As targeting neuroinflammatory processes may be of benefit across multiple neurodegenerative diseases and targeting mGlu5 modulates inflammation, it will be important to better understand the relative contribution of each cell type to pathology in order to select the most effective ligands to treat disease. This evidence concerns the gene GRM5 and neurodegenerative disease.